IO Biotech begins phase III trial with partner MSD
IO Biotech joins forces with partner MSD in the development of a new therapy for the treatment of skin cancer in combination with IO Biotech's lead candidate Keytruda. A big phase III trial now commences, and if successful, IO Biotech maintains commercial rights.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
A possible breakthrough in the treatment of metastatic melanoma patients could be on the way. Around 290,000 people are diagnosed with the skin cancer every year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
MSD sets carbon neutrality goal
For subscribers
